Dashboard
Manage Tickers

CLNNClene Inc.

Nasdaq clene.com


$ 0.39 $ 0.00 (0.03 %)    

Thursday, 09-May-2024 12:20:36 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 440.94 $ 0.48 (0.11 %)
DIA $ 392.65 $ 2.61 (0.67 %)
SPY $ 519.11 $ 1.67 (0.32 %)
TLT $ 90.17 $ 0.13 (0.14 %)
GLD $ 215.63 $ 0.93 (0.43 %)
$ 0.3899
$ 0.40
$ 0.00 x 0
$ 0.00 x 0
$ 0.39 - $ 0.41
$ 0.25 - $ 1.09
454,635
na
50.08M
$ 0.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-13-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-13-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-11-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-29-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Clen...
05/08/2024 15:43:14

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

clene-q1-eps-009-misses-008-estimate-sales-7300k-miss-12000k-estimate
Clene Q1 EPS $(0.09) Misses $(0.08) Estima...
05/08/2024 12:28:55

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
05/06/2024 20:31:06

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
04/19/2024 20:31:47

the-analyst-verdict-clene-in-the-eyes-of-5-experts
The Analyst Verdict: Clene In The Eyes Of ...
04/17/2024 20:02:08

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
04/17/2024 12:08:12

hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Clen...
04/17/2024 10:42:49

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

why-invo-bioscience-shares-are-trading-higher-by-around-73-here-are-20-stocks-moving-premarket
Why INVO Bioscience Shares Are Trading Hig...
04/17/2024 10:13:57

Shares of INVO Bioscience, Inc. (NASDAQ: INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results.

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
04/16/2024 20:31:56

clene-highlights-presentation-of-phase-2-visionary-ms-trial-data-at-2024-american-academy-of-neurology-annual-meeting-says-long-term-cnm-au8-treatment-encompassing-up-to-three-years-was-well-tolerated-no-significant-safety-findings-were-observed
Clene Highlights Presentation Of Phase 2 V...
04/16/2024 20:06:09

Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remye...

benchmark-reiterates-buy-on-clene-maintains-5-price-target
Benchmark Reiterates Buy on Clene, Maintai...
03/20/2024 12:25:43

Benchmark analyst Bruce Jackson reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $5 price target.

clene-announces-peer-reviewed-publication-characterizing-protein-corona-of-investigational-neurodegenerative-disease-drug-cnm-au8
Clene Announces Peer-Reviewed Publication ...
03/15/2024 12:03:06

Proprietary catalytic gold nanocrystals comprising Clene's investigational drug CNM-Au8® develop a protein corona upon expo...

breaking-down-clene-4-analysts-share-their-views
Breaking Down Clene: 4 Analysts Share Thei...
03/13/2024 19:00:59

hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Clen...
03/13/2024 16:44:34

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

clene-q4-earnings-insights
Clene: Q4 Earnings Insights
03/13/2024 13:40:06

clenes-cash-cash-equivalents-and-marketable-securities-of-35m-as-of-december-31-2023-will-be-sufficient-to-fund-its-operations-into-the-fourth-quarter-of-2024
Clene's Cash, Cash Equivalents And Marketa...
03/13/2024 12:11:48

clene-fy-gaap-eps-047-misses-046-estimate-sales-65400k-beat-55700k-estimate
Clene FY GAAP EPS $(0.47) Misses $(0.46) E...
03/13/2024 12:10:15

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.46) by 2....

hc-wainwright--co-maintains-buy-on-clene-maintains-7-price-target
HC Wainwright & Co. Maintains Buy on Clene...
03/11/2024 12:28:34

HC Wainwright & Co. analyst Joseph Pantginis maintains Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

clene-presents-clinical-results-of-cnm-au8-30mg-treatment-from-visionary-ms-trial-long-term-extension-at-annual-actrims-forum-2024
Clene Presents Clinical Results Of CNM-Au8...
02/29/2024 13:48:12

Long-term CNM-Au8 treatment demonstrated significant and clinically meaningful improvement of vision as measured by low contras...

hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Clen...
02/22/2024 17:20:52

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION